Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.

Poster Presentation Details:

Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA^™

Session Title: Immunomodulatory Agents and Interventions 1

Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET

Abstract Number: 1806

Speaker/Lead Author: Fay Dufort, Bicycle Therapeutics

Title: Development of in vivo models for evaluation of NK-TICA^™, novel Bicycle® tumor-targeted immune cell agonist^® designed to engage NK cells

Session Title: Immunomodulatory Agents and Interventions 1

Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET

Abstract Number: 1826

Speaker/Lead Author: Lukas Stanczuk, Bicycle Therapeutics

Title: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle^® tumor-targeted immune cell agonist^®

Session Title: Immunomodulatory Agents and Interventions 2

Date and Time: Monday, April 17, 2023 at 9:00 a.m. ET

Abstract Number: 1832

Speaker/Lead Author: Lia Luus, Bicycle Therapeutics



Title: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with Nectin-4 associated advanced malignancies

Session Title: Phase I and First-in-Human Clinical Trials in Progress

Date and Time: Tuesday, April 18, 2023 at 1:30 p.m. ET

Abstract Number: CT253

Speaker/Lead Author: Thomas R. Jeffry Evans, MBBS: School of Cancer Sciences, University of Glasgow

The posters will be made available on the Publications section of bicycletherapeutics.com following the presentations.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005025/en/